Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q3 FY20 results · Oct–Dec 2019

Sun Pharmaceutical Industries reported revenue from operations of ₹8,154.85 crore (up 5.4% from Q3 FY19) and net profit of ₹1,019.38 crore (down 30.2% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	8,154.85	7,740.19	+5.4%	8,123.35	+0.4%
Other income	119.88	193.06	−37.9%	200.85	−40.3%
Total income	8,274.73	7,933.25	+4.3%	8,324.20	−0.6%
Profit before share of associates & JVs and tax	1,351.33	1,730.11	−21.9%	1,433.38	−5.7%
Share of profit/(loss) of associates & JVs	(4.33)	1.84		(4.18)
Net profit for the period	1,019.38	1,461.03	−30.2%	1,163.17	−12.4%
Attributable to shareholders of the company	913.52	1,241.85	−26.4%	1,064.09	−14.2%
EPS, basic (₹)	3.81	5.18	−26.4%	4.43	−14.0%
Net margin (%)	12.5	18.9		14.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	3,013.55	2,261.26	+33.3%	3,373.29	−10.7%
Other income	15.36	27.76	−44.7%	258.33	−94.1%
Total income	3,028.91	2,289.02	+32.3%	3,631.62	−16.6%
Profit before tax	478.01	(65.07)	Turned profit	839.63	−43.1%
Net profit for the period	468.76	(38.68)	Turned profit	823.16	−43.1%
EPS, basic (₹)	1.95	(0.16)	Turned profit	3.43	−43.1%
Net margin (%)	15.6	-1.7		24.4

Consolidated

Filed with BSE: 07 Feb 2020, 09:52 IST
Board meeting: 06 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 07 Feb 2020, 09:52 IST
Board meeting: 06 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE